Wire
Monopar Therapeutics' Q2 Net Loss Widens
Monopar Therapeutics (MNPR) reported a Q2 net loss Wednesday of $0.62 per diluted share, compared with a loss of $0.35 a year earlier.Analysts surveyed by FactSet expected a loss of $0.66.The company did not report any revenue for the quarter.As of June 30, the company said it has $134.3 million in cash, cash equivalent and investments. It added that it expects its current funds to support operations through at least Dec. 31, 2027.Price: $115.00, Change: $+0.54, Percent Change: +0.47%
$MNPR
